Navigation Links
The interplay of genes, diet and heart disease

at consumed more than six percent of daily calories from omega-6 fatty acids displayed a blood lipid profile more prone to atherosclerosis (hardening of the arteries) and heart disease, including higher triglyceride levels.

Jose Ordovas, PhD, senior author of the study and director of the Nutrition and Genomics Laboratory at the USDA HNRCA, notes that "previous research points to polyunsaturated fatty acids like omega-3s and omega-6s as 'good' fats, thought to reduce risk of heart disease by lowering cholesterol levels if used in place of saturated fats that are mostly found in animal sources."

Ordovas continues, "Research hasn't shown us yet if there is an optimal ratio for omega- 3s to omega-6s, or if consuming a certain amount of omega-6s might negate the benefits of omega-3s. We do know that omega-6s are necessary for the body and can be a source of healthful fat in the diet, but for the 13 percent who are carriers of the particular APOA5 gene variant, consuming fewer omega-6s in relation to omega-3s may be important, as it might help reduce the risk of developing precursors to heart disease." The carriers of the variant who ate more than six percent of total calories from omega-6s had a 21 percent increase in triglyceride levels, as well as an approximately 34 percent elevation of certain atherogenic lipoprotein particles in the blood.

Carriers who consumed less than six percent of total calories from omega-6s did not show a significant increase in the lipid levels that are risk factors for heart disease. In contrast to omega-6s, higher consumption of omega-3s decreased triglyceride and atherogenic lipoprotein particle levels in the blood, regardless of a person's APOA5 gene variant.

Although the researchers analyzed information on several types of dietary fat, including saturated fat and monounsaturated fat, the interactions between diet and APOA5 were seen only with PUFAs, "adding evidence to the prominent role of PU
'"/>




Page: 1 2 3 4

Related medicine news :

1. Starvation in pregnant women can cause heart disease to their children
2. Individuals with sleep related breathing disorders more prone to heart disease
3. And now they say infections can cause heart disease!!!!
4. And now they say infections can cause heart disease!!!!
5. Award for TTK Chitra heart valve prosthesis
6. Eat greens to have a ever green heart
7. Asthma! A new warning for heart disease
8. Protein in urine foresees heart disease
9. One...just one cigarette can spoil the heart function.
10. Risk of heart disease begins in teens
11. Beer vitamin protects heart
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: The interplay genes diet and heart disease

(Date:5/15/2008)...PRNewswire-FirstCall/ -- Alexza,Pharmaceuticals, I.... Parra,has joined the company as Vice President, ...lopment and execution of quality program,strategie...nical / clinical,product candidates. Mr. Parra was...ity at Telik, Inc. in Palo Alto, California, where...
(Date:5/15/2008)...irstCall/ - QLT Inc. (NASDAQ: QLTI; TSX:,QLT) anno... agreement to,sell the land and building comprisin...eloped parcel of land in Vancouver, British Columb..., QLT will enter into a,five-year lease of space i...re very pleased that our strategic efforts to dive...
(Date:5/15/2008)...ed About Loss of Legal Remedies, SANTA MONICA, Ca...nt,with Kaiser Permanente over more than 1,000 pat...elled is an improvement on past proposals because ...repayment of losses,resulting from policy cancella...t proposals patients could not recover costs incur...
(Date:5/15/2008)...wire-FirstCall/ -- (Nasdaq: WHRT, TSX:,WHT) World ...that, on May,12, 2008, it had received a NASDAQ St...s requests for continued listing on The NASDAQ Cap... the Company did not provide a,definitive plan evi...e with,the continued listing requirements or susta...
Breaking Medicine News(10 mins):Health News:Carlos A. Parra Joins Alexza Pharmaceuticals as Vice President, Quality 2Health News:QLT Inc. announces agreement for sale of real estate 2Health News:QLT Inc. announces agreement for sale of real estate 3Health News:Consumer Watchdog Raises Concern That Health Policy Cancellation Rules Have Been Derailed in Deal With Kaiser 2Health News:Consumer Watchdog Raises Concern That Health Policy Cancellation Rules Have Been Derailed in Deal With Kaiser 3Health News:WorldHeart Announces Possible Delisting Action by NASDAQ 2Health News:WorldHeart Announces Possible Delisting Action by NASDAQ 3
...r Medco Health solutions Inc. claims that parents ...he drugs themselves. // The study examined the pre...ast year. The study also found that if one twin i...ly that the other would also take it than non-twin...
...cine that it says can ward off common allergies su...e by Cytos Biotechnology has been tested on humans...n the TB bug, reported the online edition of Daily...doubled in the past 20 years, with the condition a...
...ocacy group, Families USA, suggests that majority ... have at least one parent employed full-time//. An...be earning members. The group's executive directo...eve these are low-income people who don't work, wh...
...ple suffering a severe personality disorder are po...ealth Services are putting their best foot forward...959 Mental Health Act has indicated that chronical...stay in Mental Healthcare Hospitals, if their illn...
Other Medicine News:
(Date:5/14/2008)...wire-FirstCall/ -- Neurobiological,Technologies, I...st time at,the European Stroke Conference detailed...wo ongoing Phase 3 studies of Viprinex(TM) (ancrod...nformation as to why it,believes these studies are... stroke than previous Phase 3 clinical trials cond...
(Date:5/14/2008)...luate R7128 1000mg BID in HCV genotype 1, treatm...otypes 2 or 3 treatment-experie...ire-FirstCall/ -- Pharmasset, Inc.,(Nasdaq: VRUS ... 4-week,Phase 1 study of R7128 in combination with...) (ribavirin) in both treatment-naive and,treatmen...
(Date:5/14/2008)...ewswire-FirstCall/ -- Kosan Biosciences,Incorporat...ata will be,presented on tanespimycin, the company...ombination with Herceptin(R) in patients with HER2...nual Meeting of the American,Society of Clinical O...cago, IL, May 31 through June 3, 2008., Abstract ...
(Date:5/13/2008)...wswire/ -- Dried blood spots are emerging,as a bre...n and transport,for blood tests. In an article pub...cience and Technology (2008; 2(2):242-3), Ramakris...blood spots is a "powerful tool", for,mass disease...tries with,limited health budgets., The article h...
Breaking Medicine Technology:Neurobiological Technologies, Inc. Presents Dosing Rationale for Viprinex(TM) (ancrod) at the European Stroke Conference 2Neurobiological Technologies, Inc. Presents Dosing Rationale for Viprinex(TM) (ancrod) at the European Stroke Conference 3Neurobiological Technologies, Inc. Presents Dosing Rationale for Viprinex(TM) (ancrod) at the European Stroke Conference 4Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C 2Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C 3Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C 4Kosan Announces Data Presentations at ASCO 2008 Annual Meeting 2Kosan Announces Data Presentations at ASCO 2008 Annual Meeting 3Blood Spot Technology at ZRT Highlighted in March Issue of Journal of Diabetes Science & Technology - A Convenient Alternative to Serum Testing for Health Screening 2Inspiring Authors Tell Inspirational Stories 3A Special Writers Find Accepting Home at Lulu com 1250 1Inspiring Authors Tell Inspirational Stories 3A Special Writers Find Accepting Home at Lulu com 1250 2Exelixis Announces September 18 Webcast of Presentation at the Bank of America 2007 Investment Conference 1246 1RealAge com Suggests a Reason to Celebrate in September 21 1243 1RealAge com Suggests a Reason to Celebrate in September 21 1243 2The Lancet Publishes Major Phase 3 Study on Novel Oral Direct Thrombin Inhibitor 270 1The Lancet Publishes Major Phase 3 Study on Novel Oral Direct Thrombin Inhibitor 270 2The Lancet Publishes Major Phase 3 Study on Novel Oral Direct Thrombin Inhibitor 270 3
...RK, April 10, 2007 /PRNewswire-FirstCall/ -- ImClo...ompany today,announced that a Phase III study of E...rapy) in patients with locally advanced,unresectab...s,primary endpoint of improving overall survival. ..., a cancer,center network sponsored by the Nationa...
...0 Shown to Be Well Tolerated and Potentially Suite...April 10, 2007 /PRNewswire-FirstCall/ --,Pharmacop...t of,novel small molecule therapeutics, today anno...inical trial of PS433540, the company,s,lead inter...nsion,and diabetic nephropathy. Data from the sing...
Other Medicine Technology:Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer 2Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer 3Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer 4Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer 5Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer 6Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer 7Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer 8Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer 9Pharmacopeia Announces Positive Results from Initial DARA Clinical,Trial 2Pharmacopeia Announces Positive Results from Initial DARA Clinical,Trial 3Pharmacopeia Announces Positive Results from Initial DARA Clinical,Trial 4Pharmacopeia Announces Positive Results from Initial DARA Clinical,Trial 5
Liquichek Unassayed Chemistry Control (Human) is a comprehensive, stable, liquid product designed to monitor general and special chemistry tests.
Lyphochek Assayed Chemistry Control requires no special diluent and has good reconstituted stability for enzymes and CO2. It is assayed for most major instruments and methodologies.
Liquichek Therapeutic Drug Monitoring Control (TDM) is a liquid assayed control containing a comprehensive menu of therapeutic drugs, as well as many common ligands. Available in three levels.
Lyphochek Urine Metals Control incorporates two levels of critical trace elements, heavy metals and organic metabolites, and is ideal for environmental and industrial testing.
Medicine Products: